Fluorine Modulates Species Selectivity in the Triazolopyrimidine Class of Plasmodium falciparum Dihydroorotate Dehydrogenase Inhibitors

Malaria is one of the most serious global infectious diseases. The pyrimidine biosynthetic enzyme Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH) is an important target for antimalarial chemotherapy. We describe a detailed analysis of protein–ligand interactions between DHODH and a triazolopyrimidine-based inhibitor series to explore the effects of fluorine on affinity and species selectivity. We show that increasing fluorination dramatically increases binding to mammalian DHODHs, leading to a loss of species selectivity. Triazolopyrimidines bind Plasmodium and mammalian DHODHs in overlapping but distinct binding sites. Key hydrogen-bond and stacking interactions underlying strong binding to PfDHODH are absent in the mammalian enzymes. Increasing fluorine substitution leads to an increase in the entropic contribution to binding, suggesting that strong binding to mammalian DHODH is a consequence of an enhanced hydrophobic effect upon binding to an apolar pocket. We conclude that hydrophobic interactions between fluorine and hydrocarbons provide significant binding energy to protein–ligand interactions. Our studies define the requirements for species-selective binding to PfDHODH and show that the triazolopyrimidine scaffold can alternatively be tuned to inhibit human DHODH, an important target for autoimmune diseases.

[1]  N. White The role of anti-malarial drugs in eliminating malaria , 2008, Malaria Journal.

[2]  F. Diederich,et al.  Fluorine in Pharmaceuticals: Looking Beyond Intuition , 2007, Science.

[3]  D. Heppner The malaria vaccine--status quo 2013. , 2013, Travel medicine and infectious disease.

[4]  J. Clardy,et al.  Structures of human dihydroorotate dehydrogenase in complex with antiproliferative agents. , 2000, Structure.

[5]  David M. Shackleford,et al.  Identification of a metabolically stable triazolopyrimidine-based dihydroorotate dehydrogenase inhibitor with antimalarial activity in mice. , 2009, Journal of medicinal chemistry.

[6]  Z. Otwinowski,et al.  Processing of X-ray diffraction data collected in oscillation mode. , 1997, Methods in enzymology.

[7]  P. Rathod,et al.  Triazolopyrimidine-based dihydroorotate dehydrogenase inhibitors with potent and selective activity against the malaria parasite Plasmodium falciparum. , 2008, Journal of medicinal chemistry.

[8]  B. Kieseier,et al.  Teriflunomide for the treatment of multiple sclerosis , 2013, Clinical Neurology and Neurosurgery.

[9]  D. Wirth,et al.  Identification and Characterization of Small Molecule Inhibitors of Plasmodium falciparum Dihydroorotate Dehydrogenase* , 2008, Journal of Biological Chemistry.

[10]  Pradipsinh K Rathod,et al.  Plasmodium dihydroorotate dehydrogenase: a promising target for novel anti-malarial chemotherapy. , 2010, Infectious disorders drug targets.

[11]  Bradley I. Coleman,et al.  Novel Inhibitors of Plasmodium falciparum Dihydroorotate Dehydrogenase with Anti-malarial Activity in the Mouse Model* , 2010, The Journal of Biological Chemistry.

[12]  X. Su,et al.  Malaria biology and disease pathogenesis: insights for new treatments , 2013, Nature Medicine.

[13]  B. Genton,et al.  A molecular marker of artemisinin-resistant Plasmodium falciparum malaria , 2013, Nature.

[14]  Kevin Cowtan,et al.  research papers Acta Crystallographica Section D Biological , 2005 .

[15]  Peng Zhou,et al.  Fluorine Bonding - How Does It Work In Protein-Ligand Interactions? , 2009, J. Chem. Inf. Model..

[16]  David A. Fidock,et al.  Artemisinin-based combination therapies: a vital tool in efforts to eliminate malaria , 2009, Nature Reviews Microbiology.

[17]  Gilean McVean,et al.  Multiple populations of artemisinin-resistant Plasmodium falciparum in Cambodia , 2013, Nature Genetics.

[18]  R. Rosenfeld Nature , 2009, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[19]  R. Hallett,et al.  Artemisinin-Resistant Malaria: Research Challenges, Opportunities, and Public Health Implications , 2012, The American journal of tropical medicine and hygiene.

[20]  J. López,et al.  Molecular beam rotational spectrum of cyclobutanone-trifluoromethane: nature of weak CH...O=C and CH...F hydrogen bonds. , 2006, Chemistry.

[21]  Walther Caminati,et al.  Weak C-H...O and C-H...F-C hydrogen bonds in the oxirane-trifluoromethane dimer. , 2004, Journal of the American Chemical Society.

[22]  Michelle C. Y. Chang,et al.  Structural and biochemical studies of a fluoroacetyl-CoA-specific thioesterase reveal a molecular basis for fluorine selectivity. , 2010, Biochemistry.

[23]  Kevin Marsh,et al.  Four-year efficacy of RTS,S/AS01E and its interaction with malaria exposure. , 2013, The New England journal of medicine.

[24]  Jerry March,et al.  March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure , 2001 .

[25]  M. Roth,et al.  SAR Based Optimization of a 4-Quinoline Carboxylic Acid Analog with Potent Anti-Viral Activity. , 2013, ACS medicinal chemistry letters.

[26]  P. Rathod,et al.  Bioisosteric transformations and permutations in the triazolopyrimidine scaffold to identify the minimum pharmacophore required for inhibitory activity against Plasmodium falciparum dihydroorotate dehydrogenase. , 2012, Journal of medicinal chemistry.

[27]  P. Rathod,et al.  Analysis of flavin oxidation and electron-transfer inhibition in Plasmodium falciparum dihydroorotate dehydrogenase. , 2008, Biochemistry.

[28]  E. Johansson,et al.  Inhibitor binding in a class 2 dihydroorotate dehydrogenase causes variations in the membrane‐associated N‐terminal domain , 2004, Protein science : a publication of the Protein Society.

[29]  G. Murshudov,et al.  Refinement of macromolecular structures by the maximum-likelihood method. , 1997, Acta crystallographica. Section D, Biological crystallography.

[30]  J. Burrows,et al.  Designing the next generation of medicines for malaria control and eradication , 2013, Malaria Journal.

[31]  B. Buer,et al.  Fluorine: A new element in protein design , 2012, Protein science : a publication of the Protein Society.

[32]  Airlie J. McCoy,et al.  Solving structures of protein complexes by molecular replacement with Phaser , 2006, Acta crystallographica. Section D, Biological crystallography.

[33]  Nicholas J White,et al.  Antimalarial drug resistance. , 2004, The Journal of clinical investigation.

[34]  P. Rathod,et al.  High-throughput Screening for Potent and Selective Inhibitors of Plasmodium falciparum Dihydroorotate Dehydrogenase* , 2005, Journal of Biological Chemistry.

[35]  P. Vidalain,et al.  On dihydroorotate dehydrogenases and their inhibitors and uses. , 2013, Journal of medicinal chemistry.

[36]  David M. Shackleford,et al.  Structure-guided lead optimization of triazolopyrimidine-ring substituents identifies potent Plasmodium falciparum dihydroorotate dehydrogenase inhibitors with clinical candidate potential. , 2011, Journal of medicinal chemistry.

[37]  Peter Schuck,et al.  High-precision isothermal titration calorimetry with automated peak-shape analysis. , 2012, Analytical chemistry.

[38]  David M. Shackleford,et al.  Lead optimization of aryl and aralkyl amine-based triazolopyrimidine inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase with antimalarial activity in mice. , 2011, Journal of medicinal chemistry.

[39]  Werner Kaminsky,et al.  Structural Plasticity of Malaria Dihydroorotate Dehydrogenase Allows Selective Binding of Diverse Chemical Scaffolds* , 2009, The Journal of Biological Chemistry.

[40]  T. Wells,et al.  New medicines to improve control and contribute to the eradication of malaria , 2010, Malaria Journal.

[41]  P. Ringwald,et al.  Artemisinin resistance is a clear and present danger. , 2013, Trends in parasitology.

[42]  Darrell E Hurt,et al.  Structure of Plasmodium falciparum dihydroorotate dehydrogenase with a bound inhibitor. , 2006, Acta crystallographica. Section D, Biological crystallography.